Ritratto di Silverio.Tomao@uniroma1.it

Il martedi mattina, ore 12.00 presso ICOT di Latina, Via Faggiana (obbligatoria la prenotazione al numero 3487464784)
Il Giovedi pomeriggio, ore 15.30 presso Istituto di Patologia Generale, Viale Regina Elena 324, Roma (obbligatoria la prenotazione al numero 3487464784)

Titolo Rivista Anno
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 2021
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era JOURNAL OF TRANSLATIONAL MEDICINE 2021
Metastatic renal cell carcinoma management: from molecular mechanism to clinical practice FRONTIERS IN ONCOLOGY 2021
In vivo imaging-based techniques for early diagnosis of oral potentially malignant disorders—systematic review and meta-analysis INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2021
Role of chemotherapy in vulvar cancers: time to rethink standard of care? CANCERS 2021
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence JOURNAL OF CELLULAR PHYSIOLOGY 2020
Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens COMMUNICATIONS BIOLOGY 2020
Expression of er, pgr, her-2, and ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy CANCER CHEMOTHERAPY AND PHARMACOLOGY 2020
Fertility and reproduction in breast cancer patients BREAST CANCER RESEARCH AND TREATMENT 2020
Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial THE LANCET ONCOLOGY 2020
Metachronous and synchronous cancers in patients with neuroendocrine tumors ONCOLOGY 2020
The 5-Ws of immunotherapy in head and neck cancer CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 2020
Neoadjuvant immune-checkpoint blockade in triple-negative breast cancer: current evidence and literature-based meta-analysis of randomized trials CANCERS 2020
Multimodal treatment for local recurrent malignant gliomas: resurgery and/or reirradiation followed by chemotherapy MOLECULAR AND CLINICAL ONCOLOGY 2019
Radium‑223 in patients with metastatic castration‑resistant prostate cancer: efficacy and safety in clinical practice ONCOLOGY LETTERS 2019
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience JOURNAL OF CELLULAR PHYSIOLOGY 2019
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting INTERNATIONAL JOURNAL OF CANCER 2019
RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition JOURNAL OF THE NATIONAL CANCER INSTITUTE 2019
Paclitaxel and Alisertib in recurrent ovarian cancer JAMA ONCOLOGY 2019